NCT02059564View on ClinicalTrials.gov

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

PHASE1UnknownINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
Diabetes Mellitus
Interventions
DRUG

HM11260C

doses of 6 mg, 16 mg

DRUG

Placebo

Normal saline solution

DRUG

Victoza

doses of 1.8 mg

Trial Locations (1)

Unknown

RECRUITING

Hanmi, California City

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02059564 - A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter